Corcept Therapeutics (NASDAQ:CORT) Shares Gap Up Following Insider Buying Activity

Corcept Therapeutics Incorporated (NASDAQ:CORT) gapped up prior to trading on Friday after an insider bought additional shares in the company. The stock had previously closed at $34.08, but opened at $35.50. Corcept Therapeutics shares last traded at $36.2060, with a volume of 409,583 shares changing hands.

Specifically, Director G Leonard Baker, Jr. bought 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was bought at an average price of $33.14 per share, with a total value of $3,314,000.00. Following the completion of the transaction, the director directly owned 1,146,631 shares of the company’s stock, valued at approximately $37,999,351.34. The trade was a 9.55% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CORT. Wolfe Research downgraded Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a research report on Wednesday, December 31st. UBS Group assumed coverage on Corcept Therapeutics in a research report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price objective for the company. HC Wainwright dropped their target price on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Zacks Research lowered Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Finally, Truist Financial set a $50.00 price target on Corcept Therapeutics in a research note on Wednesday, December 31st. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Corcept Therapeutics currently has an average rating of “Hold” and a consensus price target of $77.17.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Director G. Leonard Baker Jr. bought 100,000 shares (~$3.3M) at about $33.14 on March 17, a meaningful insider purchase that signals management confidence and can support short‑term demand. Read More.
• Neutral Sentiment: Short‑interest reports for March 19–20 show effectively zero reported short interest (days‑to‑cover ≈ 0), which appears anomalous and likely reflects reporting quirks rather than a genuine absence of short sellers; this creates uncertainty about short‑seller pressure signals.
• Negative Sentiment: Multiple shareholder‑rights firms (Hagens Berman, Schall, DJS, Pomerantz, Rosen, Glancy, others) have issued class‑action/lead‑plaintiff notices tied to alleged FDA issues and a federal court patent loss — a concentrated legal PR wave that raises litigation risk, could increase future liabilities, and likely weighs on investor confidence. Read More. Read More.
• Negative Sentiment: Zacks Research sharply cut EPS forecasts across 2026–2027 and maintains a “Strong Sell” stance — analyst downgrades and lower near‑term earnings expectations increase downside pressure on valuation and can amplify selling if guidance or legal exposure worsens. Read More.

Corcept Therapeutics Price Performance

The stock has a 50 day moving average of $37.46 and a 200-day moving average of $61.93. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92. The company has a market cap of $3.68 billion, a PE ratio of 42.24 and a beta of 0.29.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The firm had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. During the same quarter in the previous year, the firm posted $0.26 EPS. The firm’s revenue for the quarter was up 11.1% compared to the same quarter last year. Equities analysts predict that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Institutional Investors Weigh In On Corcept Therapeutics

A number of large investors have recently bought and sold shares of the company. Torren Management LLC acquired a new position in Corcept Therapeutics in the 4th quarter worth approximately $25,000. Advisory Services Network LLC acquired a new stake in Corcept Therapeutics during the 3rd quarter valued at approximately $25,000. Clearstead Advisors LLC boosted its holdings in shares of Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 193 shares during the last quarter. Atlas Capital Advisors Inc. purchased a new stake in shares of Corcept Therapeutics in the 4th quarter valued at $31,000. Finally, Hantz Financial Services Inc. increased its stake in shares of Corcept Therapeutics by 113.7% in the fourth quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 524 shares during the period. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.